PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES

Bibliographic Details
Main Authors:	Oguz Altunok, Istemi Serin, Osman Yokus
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000975676.88150.33

Similar Items

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
by: Ismail Yildiz, et al.
Published: (2017-01-01)

Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
by: Nikhil Rabade, et al.
Published: (2018-01-01)

Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
by: Michelle Maccarini Barcelos, et al.
Published: (2011-01-01)

PB2237: NON-THROMBOTIC INCREASED PORTAL VENOUS PRESSURE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: IS IT JUST A HYPOTHESIS?
by: Osman Yokus, et al.
Published: (2023-08-01)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
by: Kai Wille, et al.
Published: (2023-08-01)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
by: Aleksandra Mroczkowska-Bękarciak, et al.
Published: (2023-09-01)

The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
by: Strickland, M, et al.
Published: (2021)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
by: Enrico La Spina, et al.
Published: (2023-02-01)

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
by: Antonia Beitzen-Heineke, et al.
Published: (2021-09-01)

PB2191: A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
by: Mehmet Baysal, et al.
Published: (2023-08-01)

Diagnosis- and Prognosis-Related Gene Alterations in <i>BCR::ABL1</i>-Negative Myeloproliferative Neoplasms
by: Soji Morishita, et al.
Published: (2023-08-01)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
by: Alessandro Allegra, et al.
Published: (2020-10-01)

VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms
by: Grażyna Gadomska, et al.
Published: (2017-01-01)

Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
by: Xiaolan Lin, et al.
Published: (2020-02-01)

Mutation and Lineage Analysis of DNMT3A in BCR-ABL1-negative Chronic Myeloproliferative Neoplasms
by: Huan-Chau Lin, et al.
Published: (2013-09-01)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
by: Moysés Antonio Porto-Soares, et al.
Published: (2020-07-01)

Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
by: Hye-Ran Kim, et al.
Published: (2013-01-01)

P1053: NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
by: Mirjana Cvetkovic, et al.
Published: (2023-08-01)

SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment.
by: Özlem Demirel, et al.
Published: (2017-01-01)

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of <i>BCR::ABL1</i>-Negative Myeloproliferative Neoplasm
by: Norman Abbou, et al.
Published: (2022-12-01)

Aberrant Activation-Induced Cytidine Deaminase Gene Expression Links BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
by: Hasan Dermenci, et al.
Published: (2022-06-01)

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
by: Jinyong Kim, et al.
Published: (2021-09-01)

PB2245: POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?
by: Osman Yokus, et al.
Published: (2023-08-01)

Dominance of mutations in epigenetic regulators and a diversity of signaling alterations in blast-phase BCR::ABL1-negative myeloproliferative neoplasms
by: Gurban, P, et al.
Published: (2024)

PB2400: THE EFFECT OF BONE MARROW CD4/CD8+ RATIO ON RESPONSE TO TREATMENT AND SURVIVAL IN LYMPHOMAS
by: Vahit Can Cavdar, et al.
Published: (2023-08-01)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
by: Osman Yokus, et al.
Published: (2023-08-01)

Gene aberrations and methylation analysis of JAK/stat and toll-like receptor downstream signalling in BCR-ABL-negative myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms overlap syndromes
by: Cai, Chia Yuh
Published: (2021)

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
by: Baxter, E, et al.
Published: (2003)

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL negative chronic myeloproliferative disorders.
by: Cross, N, et al.
Published: (2002)

Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms
by: Alline Didone, et al.
Published: (2016-04-01)

CORRELATION BETWEEN JAK2V617F MUTATIONAL BURDEN AND THE DEGREE OF ANGIOGENESIS IN THE BONE MARROW OF BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
by: Liana Gercheva, et al.
Published: (2014-09-01)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
by: Daniele Cattaneo, et al.
Published: (2021-11-01)

Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
by: Dambrauskienė R, et al.
Published: (2017-06-01)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
by: Melike Keskin, et al.
Published: (2023-08-01)

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome
by: Oriol Plans Galván, et al.
Published: (2018-04-01)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
by: Mian Afsar, et al.
Published: (2012-09-01)

Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report
by: A, Alia Suzana, et al.
Published: (2023)

FISH mapping of Philadelphia negative <it>BCR/ABL1 </it>positive CML
by: Marin David, et al.
Published: (2008-07-01)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
by: Diletta Fontana, et al.
Published: (2021-11-01)

BCR:ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN AND ADOLESCENTS: INCREASED DISEASE BURDEN IN PATIENTS WITH JAK2 MUTATION, UNMET DIAGNOSTIC NEEDS AND OPTIMAL TREATMENT OPTIONS
by: Charikleia Kelaidi, et al.
Published: (2023-12-01)